Ava Boswell, MD
Psychiatry · Albuquerque, NMNPI 1679969497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $280 and has fallen 68.5% since, to $88 in 2025.
Across 34 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$153
- Neurocrine Biosciences, Inc.$138
- Johnson & Johnson$112
- Alkermes, Inc.$66
- Biogen$64
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$59
- plus $158 from 5 others
What the payments were for
- Food & beverage$70994%
- Education$436%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $153 |
| Neurocrine Biosciences, Inc. | 7 | $138 |
| Johnson & Johnson | 2 | $112 |
| Alkermes, Inc. | 3 | $66 |
| Biogen | 2 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $32 |
| Lundbeck LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$751 in reported general payments places this provider in the 80th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 12 | $5,532 |
| Aripiprazole | 28 | $1,430 |
| Clomipramine Hcl | 27 | $1,336 |
| Bupropion XlBupropion Hcl | 25 | $565 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $532 |
| Amitriptyline Hcl | 24 | $446 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $407 |
| Trazodone Hcl | 45 | $368 |
| Buspirone Hcl | 23 | $326 |
| Perphenazine | 12 | $318 |
| Duloxetine Hcl | 16 | $318 |
| Escitalopram Oxalate | 26 | $263 |
| Lamotrigine | 41 | $246 |
| Memantine Hcl | 15 | $214 |
| Risperidone | 20 | $212 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- David EarlAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.